Haemonetics 

$60.2
0
+$0+0% Wednesday 03:14

統計

當日最高
61
當日最低
60
52週高點
-
52週低點
-
成交量
642
平均成交量
-
市值
2.8B
本益比
-
股息殖利率
-
股息
-

即將到來

財報

7May預期
Q3 2025
Q4 2025
下一步
1.11
1.18
1.24
1.31
預期EPS
1.271756
實際EPS
不適用

財務

12.32%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.72B營收
335.36M淨利

分析師評級

$85.00平均目標價
最高預估為 99.00。
來自過去6個月內的 7 則評分。這不是投資建議。
買入
57%
持有
43%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 HAE.BOATS 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
執行長
Mr. Christopher A. Simon
員工
3023
國家
DE
ISIN
US4050241003

上市

0 Comments

分享你的想法

FAQ

Haemonetics 今天的股價是多少?
HAE.BOATS 目前價格為 $60.2 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Haemonetics 股價表現。
Haemonetics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Haemonetics 的股票以代號 HAE.BOATS 進行交易。
Haemonetics 的市值是多少?
今天 Haemonetics 的市值為 2.8B
Haemonetics 下一次財報日期是什麼時候?
Haemonetics 將於 May 07, 2026 公布下一次財報。
Haemonetics 上一季度的財報如何?
HAE.BOATS 上一季度的財報為每股 1.31 USD,預估為 1.25 USD,帶來 +4.82% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Haemonetics 去年的營收是多少?
Haemonetics 去年的營收為 2.72BUSD。
Haemonetics 去年的淨利是多少?
HAE.BOATS 去年的淨收益為 335.36MUSD。
Haemonetics 有多少名員工?
截至 April 09, 2026,公司共有 3,023 名員工。
Haemonetics 位於哪個產業?
Haemonetics從事於Health Care產業。
Haemonetics 何時完成拆股?
Haemonetics 最近沒有進行任何拆股。
Haemonetics 的總部在哪裡?
Haemonetics 的總部位於 DE 的 Boston。